Medical Research Council, Laboratory of Molecular Biology, Cambridge University, Cambridgeshire CB2 0QH, United Kingdom; email:
Annu Rev Physiol. 2019 Feb 10;81:429-452. doi: 10.1146/annurev-physiol-020518-114630.
Although, as the major organ of gas exchange, the lung is considered a nonlymphoid organ, an interconnected network of lung-resident innate cells, including epithelial cells, dendritic cells, macrophages, and natural killer cells is crucial for its protection. These cells provide defense against a daily assault by airborne bacteria, viruses, and fungi, as well as prevent the development of cancer, allergy, and the outgrowth of commensals. Our understanding of this innate immune environment has recently changed with the discovery of a family of innate lymphoid cells (ILCs): ILC1s, ILC2s, and ILC3s. All lack adaptive antigen receptors but can provide a substantial and rapid source of IFN-γ, IL-5 and IL-13, and IL-17A or IL-22, respectively. Their ability to afford immediate protection to the lung and to influence subsequent adaptive immune responses highlights the importance of understanding ILC-regulated immunity for the design of future therapeutic interventions.
虽然肺作为气体交换的主要器官被认为是非淋巴器官,但肺驻留固有细胞(包括上皮细胞、树突状细胞、巨噬细胞和自然杀伤细胞)的互联网络对于其保护至关重要。这些细胞提供了对空气中细菌、病毒和真菌的日常攻击的防御,防止癌症、过敏和共生体的生长。随着先天淋巴样细胞(ILCs)家族的发现,我们对这种固有免疫环境的理解最近发生了变化:ILC1、ILC2 和 ILC3。所有这些细胞都缺乏适应性抗原受体,但可以分别提供大量和快速的 IFN-γ、IL-5 和 IL-13,以及 IL-17A 或 IL-22。它们能够立即为肺部提供保护,并影响随后的适应性免疫反应,这凸显了理解 ILC 调节免疫对未来治疗干预措施设计的重要性。